Shopping Cart
Remove All
Your shopping cart is currently empty
Osunprotafib
Copy Product Info
🥰Excellent
Catalog No. T61699Cas No. 2489404-97-7
Alias Osunprotafib, AC484, AC 484, ABBV-CLS-484
Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. [1] Osunprotafib (ABBV-CLS-484) stimulates the tumor microenvironment and promotes natural killer cell and CD8 T cell function and enhances T cell anti-tumor immunity by enhancing JAK-STAT signaling and reducing T cell dysfunction. [2]
Osunprotafib
Copy Product Info🥰Excellent
Purity: 99.91%
Catalog No. T61699Alias Osunprotafib, AC484, AC 484, ABBV-CLS-484Cas No. 2489404-97-7
Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. [1] Osunprotafib (ABBV-CLS-484) stimulates the tumor microenvironment and promotes natural killer cell and CD8 T cell function and enhances T cell anti-tumor immunity by enhancing JAK-STAT signaling and reducing T cell dysfunction. [2]
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $455 | In Stock | In Stock | |
| 5 mg | $1,360 | In Stock | In Stock | |
| 10 mg | $2,150 | In Stock | In Stock | |
| 25 mg | $3,730 | In Stock | In Stock | |
| 50 mg | $4,930 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.91%
ee:98.36%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. [1] Osunprotafib (ABBV-CLS-484) stimulates the tumor microenvironment and promotes natural killer cell and CD8 T cell function and enhances T cell anti-tumor immunity by enhancing JAK-STAT signaling and reducing T cell dysfunction. [2] |
| Targets&IC50 | PTP1N:2.5 nM, PTP2N:1.8 nM, PTPN2/PTPN1:0.176 μM (EC50) |
| In vitro | Osunprotafib (ABBV-CLS-484) dose-dependently increased STAT5 phosphorylation to similar levels in whole blood from healthy donors and cancer patients; Osunprotafib (ABBV-CLS-484) increased IFNγ-induced STAT1 phosphorylation and CXCL10 production in blood samples from healthy donors and cancer patients, suggesting that Osunprotafib (ABBV-CLS-484)-enhanced pathway engagement leads to enhanced downstream functional effects; Osunprotafib (ABBV-CLS-484) increased T cell activation and function in human whole blood, as indicated by dose-dependent increases in CD69 expression and IFNγ and TNF production after TCR stimulation; Osunprotafib (ABBV-CLS-484) inhibition of PTPN2/N1 enhances human immune cell activation. [2] |
| In vivo | METHODS: Mice with systemic Ptpn2 deletion were administered oral doses of Osunprotafib (ABBV-CLS-484) at 3/10/100 mg/kg twice daily in an attempt to determine whether oral systemic inhibition of PTPN2/N1 could be a safe and effective immunotherapy RESULTS Circulating chemokines, including CXCL10 and CXCL9, increased 2-3-fold at a dose of 10 mg kg-1 twice daily; a dose of 100 mg/kg twice daily resulted in significant Systemic immune activation, manifested by significant increases in circulating cytotoxic granzyme B (GZMB) CD8 T cells and cytokines such as CXCL10 and CXCL9. METHODS: Animals with tumors were evaluated at doses of 50, 100, and 150 mg/kg-1 once daily and significant changes in body condition score or body weight were observed. RESULTS No significant changes in body weight were observed with Osunprotafib (ABBV-CLS-484), which was tolerated in naive rats at doses up to 300 mg kg-1/day for 28 days. The most notable finding was a dose-dependent infiltration of immune cells in the kidneys, joints and liver, and it was also found that Osunprotafib (ABBV-CLS-484) has a relatively short half-life, allowing for rapid discontinuation of treatment, and thus faster than antibody-based therapies. effectively resolve inflammatory conditions. [2] |
| Synonyms | Osunprotafib, AC484, AC 484, ABBV-CLS-484 |
| Molecular Weight | 385.45 |
| Formula | C17H24FN3O4S |
| Cas No. | 2489404-97-7 |
| Smiles | CC(C)CCN[C@@H]1CCc2cc(O)c(N3CC(=O)NS3(=O)=O)c(F)c2C1 |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 19 mg/mL (49.29 mM), Sonication is recommended.  H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1.5 mg/mL (3.89 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Osunprotafib | purchase Osunprotafib | Osunprotafib cost | order Osunprotafib | Osunprotafib chemical structure | Osunprotafib in vivo | Osunprotafib in vitro | Osunprotafib formula | Osunprotafib molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.